Treace Medical Concepts Disappoints On Q3 Results, Lowers FY23 Guidance
Portfolio Pulse from Ryan Gustafson
Treace Medical Concepts Inc (NASDAQ:TMCI) reported worse-than-expected Q3 results and lowered its full-year 2023 revenue guidance below estimates. The company reported earnings losses of 28 cents per share, missing the analyst consensus estimate of losses of 26 cents. Quarterly sales were $40.76 million, missing the analyst consensus estimate of $42.05 million. The company lowered its full-year revenue guidance from between $191 million and $197 million to between $182 million and $186 million.
November 09, 2023 | 10:27 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Treace Medical Concepts Inc reported disappointing Q3 results and lowered its FY23 revenue guidance, which could negatively impact its stock price.
Treace Medical Concepts Inc reported worse-than-expected Q3 results and lowered its full-year 2023 revenue guidance below estimates. This negative financial performance and outlook could lead to a decrease in investor confidence and a drop in the company's stock price.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100